A man wearing goggles and a mask.

Empowering Academic Researchers

Are you an academic researcher seeking support to bring your innovative ideas to life? Look no further. Medosome Biotec is your strategic partner in advancing next-generation technologies from conception to market realization.

We seek funding from a variety of sources including the Small Business Innovative Research and Small Business Technology Transfer programs, angel investors, early stage seed capital funds, patient advocacy groups, strategic partners and crowd funding. 

We fuel innovation in the sciences by connecting passionate investors with top researchers who are working on breakthrough solutions to persistent global health problems.

Academic Researchers and University Technology Transfer Offices

WHY NOT TAKE ADVANTAGE OF THE SMALL BUSINESS INNOVATION RESEARCH GRANT PROGRAM?

The SBIR/STTR programs are the nation's largest source of early stage / high risk R&D funding for small business.  Approximately $2.5 billion is awarded through this program each year via participating government agencies.  These agencies include:  HHS/ NIH, NSF, DOD, ED, NASA,  DOE, USDA and others.

Click the logo below for more information

A logo for sbir, america 's social security institute.

To qualify for SBIR/STTR grants a faculty member must form or work with a small business entity. We can help you do that!

Medosome Biotec, LLC works with faculty members to prepare and submit successful SBIR/STTR grant proposals.

Upon funding, Medosme works collaboratively with the faculty member toward the goal of submitting an Investigations New Drug (IND) application to the FDA. Medosome pursues other funding sources as well as strategic partners with the goal of submitting a New Drug Application (NDA) for marketing approval (See report on the drug approval process).

A commercialization strategy could involve establishing a new business entity (a spin-off company). We have launched several new entities with – and for the benefit of – the company’s faculty collaborator. See our latest spin-off company: Nuteric Natural Health Products, LLC http://www.nutericnaturalhealthproducts.com)

We look forward to working with you to develop your technology

For more information contact Richard Wagner at [email protected]

A person pouring liquid into a glass.
A microscope is shown with focus on the lens.

Partnership with Clinical Stage Pharmaceutical Companies

Medosome Biotec specializes in developing early-stage technologies from preclinical through IND/Phase I. As part of its business model, Medosome strategically aligns itself with clinical-stage pharmaceutical companies to advance a promising drug toward FDA marketing approval and commercialization. This collaborative approach allows Medosome to focus on its core strengths in early-stage technologies while benefiting from the clinical development capabilities of its strategic partners. Ultimately, these partnerships enhance the chances of successful development and commercialization of innovative therapies for patients in need.

Funding Research Excellence

At Medosome Biotec, we recognize the importance of supporting cutting-edge research. We provide funding opportunities to researchers and professors with promising projects in the realm of next-generation technologies.

Navigating from Lab to Market

With our expertise and resources, we guide researchers through the complex journey from laboratory discovery to commercial success. Our collaborative approach ensures that groundbreaking ideas are effectively translated into market-ready solutions.

Accelerating Innovation

By partnering with Medosome Biotec researchers gain access to a wealth of resources and support services designed to accelerate innovation. From funding assistance to regulatory guidance, we're committed to driving progress in the field of next-generation technologies.

Connect With Us

Ready to take your research to the next level? Reach out to us to learn more about partnership opportunities with Medosome Biotec. Let's collaborate to transform your ideas into impactful solutions for the future.